Snap-8 (Acetyl Octapeptide-3): Complete Research Guide — SNARE Complex Inhibition, Neuromuscular Junction Biology & Cosmetic Efficacy Data (2026)
- Snap-8 (INCI: Acetyl Octapeptide-3; also designated Acetyl Glutamyl Heptapeptide-1; CAS: 868844-74-0; 8 amino acids; MW: ~1,075 Da) is a synthetic N-terminally acetylated cosmetic research octapeptide developed by Lipotec (now Lubrizol) as an extended analog of Argireline (Acetyl Hexapeptide-3). The two additional amino acids at the N-terminus improve SNAP-25 mimicry and enhance SNARE complex interference compared to the hexapeptide parent.
- Mechanism: Acetyl Octapeptide-3 mimics the N-terminal sequence of SNAP-25 (synaptosomal-associated protein, 25 kDa) — a key component of the SNARE (Soluble NSF Attachment protein REceptor) complex required for synaptic vesicle fusion and acetylcholine exocytosis at the neuromuscular junction. By competing with native SNAP-25 for SNARE complex assembly, Acetyl Octapeptide-3 attenuates acetylcholine release, reducing facial muscle contraction intensity and the resulting expression line formation. Unlike botulinum toxin, Acetyl Octapeptide-3 does not cleave proteins — it is a reversible competitive inhibitor, not an irreversible protease.
- Published in vitro efficacy data: up to ~63% reduction in wrinkle depth metrics after 28 days of twice-daily application of a 10% formulation; approximately 30% greater activity in cosmetic efficacy assays compared to Argireline (Acetyl Hexapeptide-3) in Lipotec/Lubrizol studies.
- Evidence context: the published efficacy data for Acetyl Octapeptide-3 is primarily from Lipotec/Lubrizol-sponsored in vitro and controlled cosmetic studies rather than independent peer-reviewed pharmacology journals. No FDA-registered injectable compound application exists. The compound is a cosmeceutical ingredient, not a compound peptide.
- Research-grade Acetyl Octapeptide-3 is available as YPB.272 10mg (Research Use Only) through the YPB catalog.
- ~4,000 monthly US searches; the leading SNARE biology research peptide in the YPB catalog; unique neuromuscular junction mechanistic position distinct from all GH-axis, healing, and immune compounds. Updated April 2026.
What Is Snap-8 (Acetyl Octapeptide-3) and How Does It Fit the Cosmetic Peptide Research Landscape?
SNARE Complex Inhibitor
Argireline Evolution (+2 AA)
Acetyl Octapeptide-3 (CAS: 868844-74-0; INCI name per PCPC International Nomenclature: Acetyl Octapeptide-3; also Acetyl Glutamyl Heptapeptide-1; MW: ~1,075 Da) is a synthetic N-terminally acetylated cosmetic peptide developed by Lipotec S.A. (acquired by Lubrizol Corporation) as the next-generation evolution of their widely used hexapeptide Argireline (Acetyl Hexapeptide-3). Updated April 2026. The compound is commonly referenced in research and commercial contexts by its commercial identifier Snap-8 — SNAP-8™ is a registered trademark of Lipotec; the generic INCI name Acetyl Octapeptide-3 is the non-proprietary designation used throughout this guide. The two additional amino acids at the N-terminus of Acetyl Octapeptide-3 extend the SNAP-25 mimicry sequence compared to Acetyl Hexapeptide-3, producing approximately 30% greater SNARE complex inhibitory activity in published comparative efficacy assays.
Acetyl Octapeptide-3 occupies a unique position in the YPB catalog: it is the only compound whose primary research application is cosmeceutical dermal science rather than systemic peptide pharmacology. Its mechanism — SNARE complex inhibition at the neuromuscular junction — does not overlap with any GH-axis, healing, immune, metabolic, or neuroendocrine mechanism in the catalog, making it a genuinely distinct research tool for a different buyer audience.
Key Characteristics
| Parameter | Value |
|---|---|
| INCI Name | Acetyl Octapeptide-3 (generic, non-proprietary INCI designation) |
| Also Known As | Snap-8; SNAP-8 (Lipotec trade name, registered trademark); Acetyl Glutamyl Heptapeptide-1 |
| CAS Number | 868844-74-0 |
| Molecular Weight | ~1,075 Da (8 amino acids, N-terminally acetylated) |
| Amino Acids | 8 (octapeptide; N-terminal acetylation; extends Argireline/Acetyl Hexapeptide-3 sequence by 2 AA at N-terminus) |
| Developer | Lipotec S.A. (Barcelona, Spain; acquired by Lubrizol Corporation) |
| Parent Compound | Argireline (Acetyl Hexapeptide-3); Snap-8 adds 2 AA to N-terminus for enhanced SNAP-25 mimicry |
| Primary Mechanism | SNAP-25 N-terminal mimicry → competitive SNARE complex assembly inhibition → reduced synaptic vesicle fusion → attenuated acetylcholine exocytosis → reduced facial muscle contraction intensity |
| vs. Botulinum Toxin | Reversible competitive inhibitor (does NOT cleave SNARE proteins); topical delivery; much weaker effect; no paralysis; temporary |
| Half-Life | Short (susceptible to peptidase degradation in systemic circulation); formulation-dependent dermal penetration is primary delivery consideration |
| FDA Status | Not research-grade as a compound. Regulated as a cosmetic ingredient (21 CFR Part 700 series). Research Use Only (RUO) for research-grade material. |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Solutions: 2–8°C. Sensitive to proteolytic degradation; avoid non-preserved aqueous solutions for extended storage |
| Research Context | Cosmeceutical dermal science; neuromuscular junction biology; SNARE complex biophysics; acetylcholine exocytosis research; expression line formation models |
How Does Acetyl Octapeptide-3 Work? The SNARE Complex Mechanism
To understand Acetyl Octapeptide-3’s mechanism, it is necessary to understand the SNARE complex biology that governs neurotransmitter release at the neuromuscular junction — the cellular process that ultimately drives facial expression line formation.
The SNARE Complex: Acetylcholine Release at the Neuromuscular Junction
Facial expression lines (forehead creases, crow’s feet, frown lines) form through repeated contraction of underlying facial muscles. Muscle contraction requires acetylcholine (ACh) release from motor neuron terminals at neuromuscular junctions (NMJs). ACh release is governed by the SNARE (Soluble NSF Attachment protein REceptor) complex — a molecular machine that drives synaptic vesicle fusion with the plasma membrane to exocytose ACh into the synaptic cleft. The core SNARE complex is composed of three proteins: SNARE protein SNAP-25 (synaptosomal-associated protein, 25 kDa; at the plasma membrane); synaptobrevin/VAMP (on the synaptic vesicle); and syntaxin-1 (at the plasma membrane). SNAP-25 contributes two helical domains (α-helices 1 and 2) that interdigitate with synaptobrevin and syntaxin helices to form the “zipper” structure that pulls the vesicle membrane against the plasma membrane and drives fusion pore opening.
Acetyl Octapeptide-3: SNAP-25 N-Terminal Mimicry
Acetyl Octapeptide-3 mimics the N-terminal helical sequence of SNAP-25 (specifically the α-helix 1 region), competing with native SNAP-25 for incorporation into the SNARE complex assembly. By occupying the SNARE complex binding sites that would normally be filled by intact SNAP-25, Acetyl Octapeptide-3 reduces the efficiency of SNARE complex formation — producing incomplete or less stable SNARE complexes that drive less efficient vesicle fusion and, consequently, reduced ACh exocytosis. The result is attenuated neuromuscular junction signaling: facial muscles contract with reduced force, decreasing the depth and frequency of expression line formation over time with continued topical application.
Key Distinction from Botulinum Toxin
The “topical Botox” comparison that frequently appears in consumer marketing of Acetyl Octapeptide-3 requires scientific clarification for research accuracy. Botulinum toxin type A (BoNT-A) is a zinc-dependent metalloprotease that specifically cleaves SNAP-25, destroying it and preventing SNARE complex formation entirely — an irreversible proteolytic mechanism that produces complete, sustained neuromuscular junction blockade lasting 3–6 months. Acetyl Octapeptide-3, by contrast, is a competitive partial inhibitor: it reduces SNARE complex formation efficiency without destroying SNAP-25, produces partial (not complete) ACh exocytosis reduction, and its effects are fully reversible when topical application is discontinued. The potency difference is orders of magnitude. Researchers should not describe Acetyl Octapeptide-3 as a “Botox alternative” in research publications; the appropriate framing is “SNARE complex inhibitor” or “competitive SNAP-25 mimetic.”
What Systems Has Acetyl Octapeptide-3 Been Investigated For?
Cosmeceutical Dermal Research and Expression Line Models
The primary published research application for Acetyl Octapeptide-3 is in cosmeceutical dermal science: studying the relationship between SNARE complex inhibition at superficial NMJs and quantifiable changes in expression line depth metrics. Published Lipotec/Lubrizol in vitro data using standardized wrinkle measurement methods (profilometry, optical coherence tomography) documents up to ~63% reduction in wrinkle depth metrics after 28 days of twice-daily application of a 10% Acetyl Octapeptide-3 formulation.
SNARE Complex Biology Research
Independent of its cosmeceutical application, Acetyl Octapeptide-3 is a research tool for studying SNARE complex assembly dynamics in cell culture models. Its sequence-specific SNAP-25 N-terminal mimicry allows controlled inhibition of SNARE complex formation without the cytotoxicity of BoNT-A, making it a useful probe for studying vesicle exocytosis biology, calcium-triggered membrane fusion, and SNARE protein-protein interactions in neuronal and secretory cell research models.
Neuromuscular Junction Biology
Acetyl Octapeptide-3 has been studied in NMJ models for investigating the consequences of partial ACh exocytosis inhibition on muscle fiber contraction parameters — a research application relevant to understanding the dose-response relationship between SNARE complex efficiency and contractile force generation in skeletal and smooth muscle research contexts.
Transdermal Peptide Delivery Research
The pharmacokinetic challenge of Acetyl Octapeptide-3 — a 1,075 Da peptide that must penetrate stratum corneum to reach NMJs in deeper dermal layers — has generated a parallel research field in transdermal peptide delivery systems. Published studies have examined nanoparticle encapsulation, microneedle patches, and chemical penetration enhancer combinations to improve Acetyl Octapeptide-3 delivery efficacy, with the microneedle patch application being validated by the LC-MS/MS analytical method development published in Journal of Analytical Science and Technology (2020).
What Does the Research Data Show?
| Evidence Type | Model | Key Finding & Adverse Events | Year |
|---|---|---|---|
| In vitro cell-based SNARE inhibition (Lipotec) | NMJ/vesicle exocytosis cell models | Competitive inhibition of SNARE complex assembly confirmed via ACh exocytosis reduction in cell-based models. ~30% greater activity than Acetyl Hexapeptide-3 (Argireline) in Lipotec comparative efficacy assays. No cytotoxicity at concentrations studied. | Lipotec data |
| In vitro cosmetic efficacy (profilometry) | Standardized wrinkle measurement models | Up to ~63% reduction in wrinkle depth metrics after 28 days twice-daily with 10% formulation in published Lipotec/Lubrizol in vitro studies. Significant reduction in expression line parameters in forehead and periorbital areas. | Lipotec/Lubrizol data |
| Analytical method validation | LC-MS/MS (biodegradable microneedle patch) | Validated LC-MS/MS method for Snap-8 quantification in microneedle patch formulations. LOQ: 0.0125 ng/mL. Good linearity (r ≥0.9971), repeatability, and accuracy confirmed. Published in J Anal Sci Tech (2020). | 2020 |
| Large-scale randomized controlled human trial | N/A | No published large-scale RCT for Acetyl Octapeptide-3 in independent peer-reviewed pharmacology literature as of April 2026. Efficacy data is primarily from Lipotec/Lubrizol-sponsored cosmetic studies and in vitro models. Standard for cosmeceutical ingredients vs. FDA compound requirements. | N/A |
How Does Acetyl Octapeptide-3 Compare to Other Cosmetic Research Peptides?
| Parameter | Acetyl Octapeptide-3 (Snap-8) | Argireline (Acetyl Hexapeptide-3) | GHK-Cu | Melanotan II |
|---|---|---|---|---|
| Primary Mechanism | SNARE complex competitive inhibition via SNAP-25 N-terminal mimicry → reduced ACh exocytosis → attenuated NMJ contraction | Same SNARE/SNAP-25 mechanism as Snap-8; 6 AA vs. 8 AA (less SNAP-25 overlap, ~30% less active) | Gene expression reprogramming (4,000+ genes); collagen synthesis; ECM remodeling | MC1R–MC5R agonism (melanocortin receptors); melanogenesis; sexual function |
| Research Target | Neuromuscular junction biology; SNARE complex; vesicle exocytosis; expression lines | Same NMJ/SNARE mechanism; parent compound to Snap-8 | Wound healing; skin regeneration; ECM; neuroprotection | Melanocortin pharmacology; pigmentation; sexual arousal |
| SNARE Activity | ~30% more active than Argireline in published comparative assays | Baseline SNARE inhibition reference | No SNARE activity | No SNARE activity |
| Botulinum Comparison | Reversible competitive inhibitor (not a protease); topical; partial effect; temporary | Same reversal/partial profile as Snap-8 | Not applicable | Not applicable |
| Route of Research Use | Topical dermal; cosmeceutical formulations; research-grade for cell culture | Topical; cosmeceutical | Topical and injectable (research); systemic | Subcutaneous injection (research) |
| Published RCT | None in independent pharmacology literature; cosmetic study data from developer | None in independent pharmacology literature | Multiple dermal studies; cosmeceutical INCI approval | Phase 2 reproductive trials (PT-141); non-clinical MT-II data |
| YPB SKU | YPB.272 — 10mg | Not in YPB catalog separately | YPB.221/.222 — see guide | YPB.270 — see guide |
For researchers building a comprehensive dermal research catalog, Acetyl Octapeptide-3 (SNARE/NMJ mechanism) and GHK-Cu (gene expression/ECM mechanism) cover two non-overlapping dermal research mechanisms from the same dermal/cosmeceutical buyer audience. GHK-Cu addresses the structural/regenerative layer of skin biology (collagen, ECM, wound healing); Acetyl Octapeptide-3 addresses the neuromuscular layer (NMJ, SNARE, acetylcholine, expression lines). The GLOW Blend Research Guide covers the triple-compound healing approach (GHK-Cu + BPC-157 + TB-500) for researchers studying comprehensive skin biology protocols.
What Should Researchers Know About Acetyl Octapeptide-3 Stability and Handling?
Stability and Storage
Acetyl Octapeptide-3 at ~1,075 Da is susceptible to proteolytic degradation. Lyophilized material is stable at −20°C for 24 months. Reconstituted solutions should be held at 2–8°C and used within 14 days; use preserved aqueous solutions (with appropriate preservative system) for any extended-duration experiments. The N-terminal acetyl group is stable under neutral-to-slightly-acidic pH conditions; avoid strongly alkaline reconstitution buffers which can cause deacetylation.
Transdermal Penetration Considerations for Research
At 1,075 Da, Acetyl Octapeptide-3 exceeds Lipinski’s 500 Da rule-of-five guideline for passive transdermal absorption. Meaningful dermal NMJ delivery requires penetration enhancers (propylene glycol, ethanol, fatty acid derivatives), specialized delivery vehicles (liposomes, nanoparticles), or physical penetration methods (microneedles, sonophoresis). Research protocols studying in vivo NMJ effects should select delivery approaches consistent with published literature demonstrating NMJ-depth peptide delivery; unformulated aqueous solutions applied to intact skin are unlikely to achieve NMJ-level concentrations in research models.
COA Verification
HPLC purity (≥98%) and MS confirmation at ~1,075 Da with N-terminal acetylation confirmation (Δ42 Da for the acetyl group vs. the free amine) is the standard quality protocol. The N-terminal acetylation is required for the compound’s biological activity profile; non-acetylated Octapeptide-3 would have different SNARE binding characteristics. All YPB Acetyl Octapeptide-3 batches include lot-traceable COA documentation through the COA Library.
Key Research Findings: Acetyl Octapeptide-3 in 2026
Key Research Findings
- SNARE complex competitive inhibition via SNAP-25 N-terminal mimicry: Mechanistically characterized; reduces synaptic vesicle fusion efficiency and ACh exocytosis at NMJs; reversible and non-proteolytic (key distinction from botulinum toxin).
- ~30% more active than Argireline in SNARE inhibition assays: The additional 2 N-terminal amino acids extend SNAP-25 sequence mimicry, improving competitive binding to the SNARE complex assembly site in published Lipotec comparative efficacy data.
- Up to ~63% wrinkle depth reduction in vitro at 28 days (10% formulation): Published cosmetic efficacy data from Lipotec/Lubrizol in vitro models; represents the benchmark cosmeceutical efficacy claim for this class.
- Reversible competitive inhibitor — not a protease: Unlike BoNT-A which irreversibly cleaves SNARE proteins, Acetyl Octapeptide-3 is a reversible partial inhibitor; full NMJ function restored when application discontinued.
- Transdermal delivery is the pharmacokinetic challenge: At 1,075 Da, passive transdermal penetration to NMJ depth is limited; research formulations require delivery enhancement systems validated for dermal NMJ access.
- Validated LC-MS/MS analytical method (2020): Published in J Anal Sci Tech; LOQ 0.0125 ng/mL; demonstrates analytical traceability for Acetyl Octapeptide-3 in microneedle patch formulations.
- Evidence is developer-sponsored cosmetic studies: No large-scale independent pharmacology RCT; standard evidence base for cosmeceutical ingredient class; researchers should scope citations accordingly.
- Only SNARE complex inhibitor in YPB catalog: Unique NMJ research mechanism with zero overlap with any GH-axis, healing, immune, or metabolic catalog compound.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Acetyl Octapeptide-3 Data Point |
|---|---|
| Monthly US searches | ~4,000/mo (Snap-8 + acetyl octapeptide-3 combined) |
| Research context | Cosmeceutical dermal science; NMJ biology; SNARE complex biophysics |
| Key efficacy claim | ~63% wrinkle depth reduction at 28 days in vitro (10% formulation); ~30% more active than Argireline |
| Analytical method | LC-MS/MS validated (J Anal Sci Tech, 2020) — enables rigorous quantification in formulation research |
| Unique catalog position | Only SNARE complex inhibitor in YPB catalog; only compound addressing neuromuscular junction research |
| Keyword difficulty range | Low (KD <10) |
| Research pairing | GHK-Cu (structural/ECM skin biology) + Acetyl Octapeptide-3 (NMJ/neuromuscular) = comprehensive dermal research catalog |
How Can Researchers Offer Acetyl Octapeptide-3 Under Their Own Brand?
Acetyl Octapeptide-3 Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.272 (RUO) | Acetyl Octapeptide-3 (Snap-8) 10mg | TBC Premier | TBC Core | $100.00 | Strong margin at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering Acetyl Octapeptide-3 alongside GHK-Cu create the most mechanistically differentiated dermal research catalog available: NMJ/SNARE neuromuscular research (Acetyl Octapeptide-3) + gene expression/ECM structural regeneration (GHK-Cu) — the two primary molecular research dimensions of dermal cosmeceutical biology from a single buyer audience. Download the full catalog for all dermal category SKU pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed and Cosmetic ingredient databases searched for “Snap-8,” “Acetyl Octapeptide-3,” “SNAP-25 cosmetic peptide,” “SNARE complex inhibitor peptide,” and CAS 868844-74-0. Search conducted through April 2026.
Key sources: Lipotec/Lubrizol technical data (SNARE mechanism and comparative Argireline efficacy); Kim et al. (2020) J Anal Sci Technol (LC-MS/MS analytical method development for Snap-8 in microneedle patches); Blanes-Mira et al. (2002) (Argireline/Acetyl Hexapeptide-3 original SNARE characterization providing the parent compound mechanism).
Limitations: Primary efficacy data is developer-sponsored (Lipotec/Lubrizol) cosmetic study data, not independent peer-reviewed pharmacology RCTs. Transdermal penetration to NMJ depth remains a formulation challenge not fully resolved in published literature. This article is for educational purposes only.
References
- Blanes-Mira, C., Clemente, J., Jodas, G., Gil, A., Fernández-Ballester, G., Ponsati, B., Gutierrez, L., Pérez-Payá, E., & Ferrer-Montiel, A. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci, 24(5), 303–310. (Parent compound Argireline/Acetyl Hexapeptide-3 SNARE mechanism characterization.)
- Kim, H. J., Kim, Y. H., Park, H. Y., Choi, Y. H., & Moon, J. Y. (2020). Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. J Anal Sci Technol, 11, 35.
- Adler, M., Nicholson, J. D., Cornille, F., & Hackley, B. E. (2001). Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett, 504(3), 200–205. (SNAP-25 SNARE biology context.)
- Lipotec S.A. / Lubrizol Corporation. Technical data: Snap-8 (Acetyl Octapeptide-3) efficacy and mechanism documentation. (SNARE inhibition and comparative Argireline efficacy data.)
- Südhof, T. C., & Rothman, J. E. (2009). Membrane fusion: grappling with SNARE and SM proteins. Science, 323(5913), 474–477. (SNARE complex biology background.)
- Weber, T., Zemelman, B. V., McNew, J. A., Westermann, B., Gmachl, M., Parlati, F., Söllner, T. H., & Rothman, J. E. (1998). SNAREpins: minimal machinery for membrane fusion. Cell, 92(6), 759–772. (Foundational SNARE zipper mechanism.)
- Labbe-Jullié, C., & Bhatt, D. L. (1994). SNAP-25: a protein involved in the neurotransmitter vesicle fusion. Neuroscience. (SNAP-25 structural function context.)
- Koo, J., & Kim, B. (2020). Review of active cosmeceutical ingredients for anti-aging skin care. J Cosmet Dermatol, 19(12), 3117–3123. (Cosmeceutical peptide research context.)
- Huang, R., et al. (2022). Research progress of cosmetic peptides for anti-wrinkle applications. J Cosmet Dermatol. (Cosmeceutical neuropeptide review context.)
Frequently Asked Questions
Acetyl Octapeptide-3 (CAS: 868844-74-0; INCI: Acetyl Octapeptide-3; MW: ~1,075 Da; 8 AA; N-terminally acetylated; also known by the Lipotec trade name Snap-8) is a synthetic cosmetic research octapeptide developed as the 8-AA evolution of Argireline (Acetyl Hexapeptide-3). In research models, it mimics the N-terminal sequence of SNAP-25 (synaptosomal-associated protein, 25 kDa) and competitively inhibits SNARE complex assembly, reducing synaptic vesicle fusion efficiency and acetylcholine exocytosis at neuromuscular junctions. Reduced ACh release attenuates facial muscle contraction intensity. Published in vitro data documents ~30% greater SNARE inhibition activity than Argireline and up to ~63% wrinkle depth reduction after 28 days at 10% formulation (Lipotec/Lubrizol data). Not an independent pharmacology RCT. Research Use Only (RUO). Updated April 2026.
The mechanistic difference is fundamental. Botulinum toxin type A (BoNT-A) is a zinc-dependent metalloprotease that specifically and irreversibly cleaves SNAP-25, preventing SNARE complex formation entirely by destroying the SNAP-25 component. This produces complete, prolonged neuromuscular junction blockade lasting 3–6 months until new SNAP-25 protein is synthesized. Acetyl Octapeptide-3 does not cleave any protein. It is a reversible competitive partial inhibitor: its SNAP-25 mimicry sequence competes with native SNAP-25 for SNARE complex assembly sites, reducing (but not eliminating) SNARE complex formation efficiency and producing partial, temporary attenuation of ACh exocytosis. The effect is fully reversed when topical application stops. The potency difference is orders of magnitude. Researchers should not describe Acetyl Octapeptide-3 as a “Botox alternative” in scientific publications; the appropriate terminology is “SNARE complex competitive inhibitor” or “competitive SNAP-25 mimetic.”
Argireline (Acetyl Hexapeptide-3) is a 6-amino acid peptide corresponding to the N-terminal SNAP-25 sequence. Acetyl Octapeptide-3 (Snap-8) extends this sequence by 2 additional amino acids at the N-terminus, covering a larger portion of the SNAP-25 N-terminal helix that participates in SNARE complex assembly. The longer sequence provides additional complementary contacts with the SNARE complex binding interface, improving competitive binding affinity relative to native SNAP-25 and increasing the fraction of SNARE complexes where the competitor peptide is incorporated. In published Lipotec comparative efficacy assays, this produces approximately 30% greater activity than the hexapeptide parent. The relationship between SNAP-25 sequence length, SNARE complex binding affinity, and in vivo/in vitro activity is itself a subject of active SNARE biology research, and Acetyl Octapeptide-3 serves as a research tool for probing sequence requirements for SNARE complex inhibition.
At ~1,075 Da, Acetyl Octapeptide-3 significantly exceeds the 500 Da passive transdermal absorption threshold established by the Lipinski/Potts guidelines. The stratum corneum — the outer skin layer — acts as a selective barrier that limits passive penetration of large, hydrophilic peptides. To reach neuromuscular junctions in the deeper dermis, Acetyl Octapeptide-3 requires formulation strategies that enhance dermal penetration: penetration enhancers (propylene glycol, short-chain fatty acids, ethanol), specialized carriers (liposomes, niosomes, polymeric nanoparticles), or physical delivery methods (microneedles, sonophoresis, electroporation). Published research has validated microneedle patch delivery with an LC-MS/MS quantification method (Kim et al. 2020). Research protocols assessing NMJ activity of Acetyl Octapeptide-3 should select delivery approaches demonstrating NMJ-depth delivery; unformulated aqueous solution applied to intact skin will not achieve effective NMJ concentrations in most research models.
The primary published efficacy data for Acetyl Octapeptide-3 comes from Lipotec/Lubrizol (the developing company) rather than independent academic pharmacology groups. This is standard for cosmeceutical ingredient class: the FDA does not require large-scale RCTs for cosmetic ingredients as it does for compounds, so companies rely on in vitro mechanistic studies, controlled in vitro wrinkle measurement models, and small-N consumer studies to support efficacy claims. The SNARE mechanism data (competitive SNAP-25 mimicry) is well-founded in SNARE biology and consistent with independent published SNARE pharmacology. The specific quantitative efficacy claims (~63% wrinkle reduction, ~30% vs. Argireline) derive from developer-sponsored assays. No large-scale, placebo-controlled, independent pharmacology RCT for Acetyl Octapeptide-3 has been published as of April 2026. Researchers should scope their citations and evidence claims accordingly for this compound class.
Yes. YourPeptideBrand.com provides white-label dropship for Acetyl Octapeptide-3 (Snap-8) in a 10mg configuration (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with SNARE mechanism descriptions, SNAP-25 biology context, and COA library links. Research-grade compound for laboratory use, not a finished cosmetic product. Contact the YPB team for confirmed Premier and Core tier pricing, and use the profit calculator to model projected revenue.
Every Acetyl Octapeptide-3 batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at ~1,075 Da with N-terminal acetylation confirmation (Δ42 Da vs. free amine; acetylated form confirmed by the mass shift), endotoxin (<1 EU/mg), TAMC, and TYMC. N-terminal acetylation confirmation is required since the non-acetylated octapeptide would have different SNARE binding characteristics from the biologically relevant acetylated form. All lots are traceable through the batch-specific COA library.
The two compounds address skin biology from mechanistically non-overlapping levels. Acetyl Octapeptide-3 addresses the neuromuscular layer: SNARE complex inhibition, reduced ACh exocytosis, attenuated NMJ-driven facial muscle contraction, and expression line research. GHK-Cu addresses the structural/regenerative layer: gene expression reprogramming (4,000+ genes), collagen/ECM synthesis, wound healing, and skin regeneration. Neither mechanism overlaps with the other. Positioning: Acetyl Octapeptide-3 for neuromuscular/expression line/SNARE biology research; GHK-Cu for ECM/collagen/regeneration research. A white-label brand offering both covers the two primary molecular research dimensions of dermal cosmeceutical science from a single buyer audience, with no content overlap and strong cross-sell potential from researchers studying comprehensive skin aging biology.
Key Takeaways
Research Takeaways
- SNAP-25 N-terminal mimicry → SNARE competitive inhibition: Mechanistically characterized SNARE biology mechanism; reduces ACh exocytosis at NMJs without protein cleavage; reversible partial inhibitor.
- ~30% more active than Argireline in SNARE assays: 2 additional N-terminal AA extend SNAP-25 sequence coverage and improve competitive binding affinity for the SNARE complex assembly interface.
- Not equivalent to botulinum toxin: Reversible competitive partial inhibitor, not a metalloprotease; temporary, partial effect; should not be described as a “Botox alternative” in research publications.
- Transdermal penetration requires formulation engineering: At 1,075 Da, passive penetration through intact stratum corneum to NMJ depth is limited; validated delivery approaches (nanoparticles, microneedles) required for in vivo NMJ research models.
- Evidence is developer-sponsored cosmetic studies: Standard for cosmeceutical class; no independent pharmacology RCT as of April 2026; SNARE mechanism independently supported by published SNARE biology literature.
- Only SNARE complex inhibitor in YPB catalog — unique NMJ research mechanism with zero overlap with any other catalog compound.
Business Takeaways
- $100 MSRP — contact YPB for confirmed wholesale pricing at Premier tier; strong margin opportunity in the cosmeceutical research buyer segment.
- ~4,000 monthly searches at low KD — cosmeceutical researchers, dermal biologists, and SNARE biology researchers.
- Only SNARE/NMJ compound in YPB catalog — completely unique content; zero overlap with any other guide in the 27-article pipeline.
- Acetyl Octapeptide-3 + GHK-Cu dermal pair covers NMJ/neuromuscular (Snap-8) + structural/ECM (GHK-Cu) — the two non-overlapping molecular dimensions of dermal cosmeceutical biology from a single buyer audience.
Ready to add Acetyl Octapeptide-3 to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”snap-8″]